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Macrophages (Mps) are essential cellular components of the innate immune system. They are released from the bone marrow as immature
monocytes and after circulating in the blood stream, migrate into tissues to undergo final differentiation into resident Mps. In general terms Mps
behavior in breast tumors, was described as being either for or against tumor growth. Under certain well defined circumstances Mps are able to kill
cells in two ways: direct tumor cytotoxicity or antibody dependent cytotoxicity. We had previously demonstrated that peritoneal Mps from LMM3
mammary tumor bearingmice (TMps) enhanced in vivo the LMM3 induced angiogenesis, promoting tumor growth whileMps from normal BALB/c
mice (NMps) did not. In this work, we demonstrate that Mps, expressing functional muscarinic acetylcholine receptors, are able to proliferate in vitro
in response to the muscarinic agonist carbachol. These peritoneal cells use two distinct metabolic pathways: TMps are primed by tumor presence and
they proliferate mainly by activating arginase pathway and by producing high levels of prostaglandin E2 via M1–M3 receptors activation. In NMps,
carbachol stimulates M2 receptors function, triggering protein kinase C activity and induces moderate prostaglandin E2 liberation via M1 receptor.
© 2007 Elsevier B.V. All rights reserved.Keywords: Muscarinic receptor; Macrophage; Proliferation; Arginase; Cyclooxygenase; Protein kinase C1. Introduction
Macrophages (Mps) are essential cellular components of the
innate immune system. They are released from the bone marrow
as immature monocytes and after circulating in the blood stream,
migrate into tissues to undergo final differentiation into resident
Mps. These cells can be found in almost all tissues of the body
and depending on the local microenvironment, acquire specia-
lized phenotypic characteristics. Mps perform a multitude of
functions essential for tissue remodelling, inflammation and
immunity, including phagocytosis, cytotoxicity and secretion of
a wide array of cytokines, growth factors, lysozymes, proteases,
complement components, coagulation factors and prostaglan-
dins [1] The first description of the presence of leukocytes in⁎ Corresponding author. Güemes 3144 1°B CP 1425, Ciudad de Buenos Aires,
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doi:10.1016/j.bbadis.2007.11.005human tumors was done by Virchow in 1864 and it was thought
to reflect the onset of cancer at sites of previous chronic in-
flammation. It has now been established that the majority of
malignant tumors contain numerous Mps as a major component
of the host leukocytic infiltrate [2]. Although most of these Mps
are derived from peripheral blood monocytes into the tumor
mass from the circulation, there are evidences of local pro-
liferation of Mps [3].
In general terms Mps behaviour in breast tumors was des-
cribed as being either for or against tumor growth. Because
multiple pathways are activated, it is likely that a complexmix of
effects would be occurring. Under certain well defined cir-
cumstances, Mps are capable of killing cells in two ways: direct
tumor cytotoxicity or antibody dependent cytotoxicity. We had
previously demonstrated that peritoneal Mps from LMM3
mammary tumor bearing mice (TMps) enhance in vivo LMM3
induced angiogenesis promoting tumor growth while Mps from
normal BALB/c mice (NMps) did not [4]. In addition, we
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induce a potent angiogenic response that is augmented by ca-
rbachol. Muscarinic acetylcholine receptors (mAChR) activa-
tion triggers arginine metabolism, prostaglandin E2 (PGE2)
synthesis and vascular endothelial growth factor production,
promoting neovascularization [5]. Here we evaluate the partici-
pation of different mAChR subtypes in NMps and TMps
proliferation, as well as the activation of muscarinic effector
enzymes: protein kinase C (PKC), arginase and cyclooxygenase
(COX), involved in carbachol proliferative action.
2. Materials and methods
2.1. Animals and tumor cell line
Female BALB/c mice, 12 weeks old, from our Animal Division were used.
Animal care was provided in accordance with the Guide for Care and Use of
Laboratory Animals (NIH Publication, 1986). The tumor cell line LMM3 was
previously selected from a spontaneous syngeneic mammary adenocarcinoma
MM3 [6]. Cell suspensions with more than 90% viability (assessed by Trypan
blue) were used. Tumor-bearingmicewere obtained by subcutaneous inoculation
of 4×105 LMM3 cells into the flank of BALB/c female mice.
2.2. Purification of peritoneal macrophages
Peritoneal cells from normal and tumor bearing mice (7 days post inocu-
lation, with similar palpable tumors) were obtained by washing the peritoneal
cavity with 5 ml D-MEM supplemented with 10% fetal calf serum (FCS). The
adherent cells from normal and tumor bearers were purified by adhesion to plastic
for 2 h. After being washed twice with PBS, adherent cells were scrapped and
resuspended in culture medium. Only cell suspensions with more than 95%
viability were used.
2.3. Proliferation assay
NMps and TMps (104 cell/well) were seeded by triplicate in 96 well plates in
200 μl D-MEMwithout FCS. Cells were stimulated during 1 h with carbachol in
the absence or presence of 1 μM atropine, 1 μM pirenzepine, 1 μM metho-
ctramine or 1 μM 4-diphenylacetoxy-N-methylpiperidine (4-DAMP), 1 μM
2-nitro-4-carboxyphenyl-N, N-diphenyl carbamate (NCDC), 100 μM NG-mono-
methyl-L-arginine (L-NMMA), 100 nM H-7, 100 μM Nω-hydroxy-L-arginine
(NOHA), 50 mM valine, 1 μM indomethacin or 100 μM NS-398. As a positive
control we included the action of lipopolysaccharide (LPS) (0.5 mg/ml) from
E. Coli plus interferon gamma (IFNγ) (100 U/ml) added during 18 h. Then,
medium was replaced by fresh D-MEM medium containing 10 μl of [6-3H]dT-
tritiated thymidine diluted 1:25 (sp.Act. 5.0 Ci/mmol, NEN, Life Science
Products). Cells were cultured for 48 h at 37 °C in a humidified 5% CO2 air
atmosphere. Then supernatants were discarded and cells were washed twice with
PBS. Cells were lysed in 200 μl NaOH 0.2 M and the content of each well was
added to 1 ml of biodegradable scintillation cocktail (Hisafe, Wallac) and counted
with about 50% efficiency. Results were expressed as [3H]-Thymidine uptake in
counts per minute.
2.4. Detection of muscarinic acetylcholine receptor subtypes by
Western blot
PurifiedMps (106 cells) were lysedwith 0.5ml 0.5%NP-40, 10mMTris–HCl,
pH 7.4 and 5 mM MgCl2, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM
NaF, 0.1 mM orthovanadate and the following protease inhibitors: 10 μg/ml
aprotinin, 10 μg/ml leupeptin, 5 mM PMSF, 50 μg/ml soybean trypsin in-
hibitor. Lysates were sonicated during 30 s and centrifuged at 3000 rpm for
10 min at 4 °C. Supernatants were centrifuged at 10,000 rpm for 20 min at 4 °C.
Resulting supernatants were stored at −80 °C. Protein concentration was
determined by the method of Lowry [7].Samples were subjected to 7.5% SDS-PAGEminigel electrophoresis seeding
30 μg protein in each lane. Standards of known molecular weight were also
seeded. After electrophoresis, proteins were transferred to nitrocellulose
membranes (Bio-Rad) and washed with distilled water. The nitrocellulose strips
were blocked in buffer 20 mM Tris–HCl, 500 mM NaCl, 0.05% Tween 20
(TBST) with 5% skimmed milk, for 1 h at 20 °C to 25 °C and subsequently
incubated overnight with goat anti-M1, anti-M2 or anti-M3 polyclonal antibodies
or rabbit anti-M4 or anti-M5 polyclonal antibodies (Santa Cruz Biotechnology)
diluted 1:100 in TBST. After several rinses with TBST, strips were incubated
with the second antibody (goat anti-mouse or rabbit anti-mouse IgG conjugated
with alkaline phosphatase and diluted 1:4000 in TBST) at 37 °C during 1 h.
Bands were revealed with a mixture of nitroblue tetrazolium chloride and
5-bromo-4chloro-3-indolylphosphate-p-toluidine salt (NBT/BCIP). Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) expression was used as loading
control. Quantification of the bands was performed with a computerized
densitometer connected to an image analyzer (Bio-Rad GS700) and is expressed
in optical density units per mm2 [8].
2.5. Protein kinase C assay
Mps were incubated alone or in the presence of carbachol (100 nM) for
10 min in the absence or presence of 100 nM H-7 to inhibit PKC activity or
muscarinic antagonists: 1 μM atropine, 1 μM pirenzepine, 1 μMmethoctramine
or 1 μM 4-DAMP and were immediately frozen at a concentration of 107 cells/
sample in liquid N2. PKC was purified from sub-cellular fractions as previously
described [9]. Enzyme activity was assayed by measuring the incorporation of
32P from [γ-32P]-ATP into histone H1. Incubations were conducted in a final
volume of 85 μl at 30 °C for 30 min. In the final concentrations, the assay
mixture contained 25 mM ATP (0.4 mCi), 10 mM magnesium acetate, 5 mM
β-mercaptoethanol, 50 mg histone H1, 20 mM HEPES, pH 7.5, and, unless
otherwise indicated, 0.2 mMCaCl2 and 10mg/ml of phosphatidylserine vesicles.
The incorporation of [32P] phosphate into histone was linear for at least 30 min.
The reaction was stopped by the addition of 2 ml ice-cold 5% trichloroacetic acid
with 10 mM H3PO4. The radioactivity retained on GF/C glass fiber filters
and after filtration was determined by counting the filters in 2 ml scintillation
fluid. PKC activity was determined after subtracting the 32P incorporation in the
absence of Ca2+ and phospholipids. Data were calculated as picomol of
phosphate incorporated into the substrate per minute and per 107 cells. Enzyme
activity was expressed as % of activity in membrane or cytosol fractions.
2.6. Prostaglandin E2 assay
PGE2 production by Mps was determined by radioimmunoassay (RIA)
according to a previously described method [10]. Purified Mps (2×106 cells/
sample) were incubated during 1 h at 37 °C in a Dubnoff bath with carbogen in
1 ml MEM without or with 100 nM carbachol in the absence or presence of
1 μM atropine, 1 μM methoctramine, 1 μM 4-DAMP, 1 μM indomethacin or
10 μM NS-398. After incubation cells were centrifuged for 10 min at 200 g and
supernatants were frozen at −80 °C until the assay was carried out. For PGE2
RIA, 100 μl samples or standards were incubated for 30 min with 500 μl rabbit
anti-PGE2 antiserum (Sigma) at 4 °C. Then 5 pg [
3H]-PGE2 (specific activity:
154 Ci/mmol; New England Nuclear) were added to each tube. All dilutions
were done in 0.01 M PBS, pH 7.4, containing 0.1% bovine serum albumin and
0.1% sodium azide. After incubation, a dextran-coated charcoal suspension was
added to separate the bound from the free fraction. The supernatants were
removed from each tube and added to 1 ml of scintillation solution (Optiphase
Hisafe 3 Wallac) to determine the amount of radioactivity present. Results are
expressed in picograms per 106 cells.
2.7. Detection of cyclooxygenase isoforms by Western blot
Purified Mps were washed twice in cold PBS and then resuspended in 300 μl
of lysis buffer (20 mM Tris–HCl, 1 mM EDTA, 10 μg/ml leupeptin, 2 μg/ml
aprotinin, 10 μg/ml dithiotreitol, 100 μg/ml Soybean trypsin inhibitor, 1 mg/ml
benzamidine). After 1 h, lysates were centrifuged at 5000 rpm during 10 min.
Resulting supernatants were stored at −80 °C. Protein concentration was
determined by the method of Lowry [7].
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seeding 30 μg protein in each lane. Standards of known molecular weight
were also seeded. After electrophoresis, proteins were transferred to
nitrocellulose membranes (Bio-Rad) at 4 °C during 18 h. Membranes were
then washed with distilled water and incubated with blocking solution (5%
skimmed milk in TBST) for 1 h at 20 °C to 25 °C. Membranes were incubated
with rabbit polyclonal anti COX-1 or COX-2 antibodies (Cayman Chemical) in
TBS for 90 min at room temperature. Then secondary anti-rabbit IgG antibody
conjugated with alkaline phosphatase was added for 1 h at 37 °C. Proteins were
visualized with NBT/BCIP and quantified by a densitometric analysis [11].
GAPDH expression was used as loading control.
2.8. Arginase activity assayArginase activity was determined in cell lysates according to previously
described methods [12]. Briefly, 105 cells treated or not with 100 nM
carbachol in the absence or presence of 100 μM NOHA, 1 μM atropine, 1 μM
pirenzepine, 1 μM methoctramine or 1 μM 4-DAMP. After being washed,
cells were lysed with 0.5 ml 0.1% Triton X-100, 25 mM Tris–HCl pH 7.4,
containing 5 mM MnCl2. The enzyme was then activated by heating at 56 °C
for 10 min. Arginine hydrolysis was performed by incubating 25 μl of the
activated lysate with 25 μl of 0.5 M arginine, pH 9.7, at 37 °C for 60 min. The
reaction was stopped in acid medium. Urea concentration was measured at
540 nm with a microplate reader. Results are expressed as micromol of urea
per hour and per 106 cells.
2.9. Detection of arginase isoforms by Western blotMps were rinsed twice with ice-cold PBS and then scrapped into 300 μl
lysis buffer: 50 mM Tris–HCl, pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 1 μg/ml
leupeptin, 1 μg/ml aprotinin and 0.1 mM PMSF. Lysis was completed by
sonication. Samples (25 μg) were subjected to 10% SDS-PAGE as it was stated
in previous methods [13]. Nitrocellulose membranes were incubated overnight
with a monoclonal anti-mouse arginase I antibody (BD Transduction
Laboratories) or with a rabbit anti-arginase II antibody (generously gifted by
Dr. Masataka Mori). The secondary antibody anti-mouse or anti-rabbit IgG
conjugated with alkaline phosphatase was added for 1 h at 37 °C. Proteins were
visualized using a mixture of NBT/BCIP and quantified by densitometric
analysis of the bands. GAPDH expression was used as loading control.2.10. Determination of cAMP LevelsFig. 1. Muscarinic receptors participation in the proliferation of macrophages
(Mps). A) Normal or LMM3 mammary tumor bearer macrophages (NMps or
TMps) were treated with different concentrations of carbachol (⁎pb0.01 vs.
Basal) in the absence or presence B) of muscarinic antagonists: 1 μM atropine
(AT), 1 μM pirenzepine (PIR), 1 μM methoctramine (MET) or 1 μM 4-DAMP.
Then cells were pulsed with [6-3H]dT-tritiated thymidine. Results are expressed
as incorporated cpm. Values are mean±SEM of four experiments performed in
triplicate. ⁎pb0.01 #pb0.05 vs. carbachol C) Western blot of muscarinic
receptors expressed in NMps or in TMps and densitometric analysis of the bands
expressed in optical density units per mm2 (O.D./mm2). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression was used as loading control.
One representative experiment of three is shown. N.D. (not detected).Mps (106 cells) were incubated in 1 ml of D-MEM in the presence of
1 mM isobutyl methyl xantine during 30 min with or without 1 μM iso-
proterenol to induce cAMP formation. Isoproterenol-stimulated Mps were
treated with 100 nM carbachol in the absence or presence of 1 μM
methoctramine or 1 μM tropicamide. Then samples were centrifuged at
1000 rpm and liberation of cAMP was assayed in supernatants. Samples
(100 ul) were treated with triethyleneamine:acetic anhydride (2:1) and after
10 min, 100 μl of [125I]-cAMP (Specific Act: 600 Ci/mmol) and 100 μl of a
rabbit polyclonal anti cAMP antibody (generously gifted by Dr. Parlow
NIDDK's National Hormone and Pituitary Program, USA) were added and
mixed with shaking at 4 °C overnight. Then 50 μl of 2% bovine
seroalbumine in distilled H2O and 2 ml of ethanol (96%) were added to
each tube and mixed. After 10 min samples were centrifuged at 3000 rpm
and supernatants were discarded. Radioactivity in pellets was detected in a
gamma counter. cAMP concentration in samples is expressed in fentomol per
106 cells/ml [14].
2.11. Drugs
All drugs were purchased from Sigma-Aldrich unless otherwise stated.
Solutions were prepared fresh daily.2.12. Statistics
Results are given as means±SEM for at least three independent experiments.
The statistical significance of differences between groups was analyzed by
ANOVA or Kruskal–Wallis, using GraphPad Prism 4; pb0.05 was considered
statistically significant.
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3.1. Proliferative actions of carbachol on macrophages
We had previously documented the presence of non neuronal
cholinergic receptors in Mps with the ability to control angio-
genesis. As shown in Fig. 1 A, treatment with carbachol sti-
mulates NMps as well as TMps proliferation only at 100 nM
concentration. In NMps, this concentration of carbachol
increased the [3H]-Thymidine incorporation by 90% in relationFig. 2. Participation of protein kinase C and cyclooxygenase in the proliferation of no
absence or presence of 1 μM 2-nitro-4-carboxyphenyl-N, N-diphenyl carbamate (
C) cyclooxygenase (COX) inhibitors 1 μM indomethacin (INDO) or 10 μMNS-398. W
was expressed in optical density units per mm2 (O.D./mm2). Glyceraldehyde-3-ph
representative experiment of three is shown B) Protein kinase C enzymatic assay in m
the absence or presence of: 1 μM atropine (AT), 1 μM pirenzepine (PIR), 1 μM met
shown D) Prostaglandin E2 (PGE2) determination in the culture supernatants of NMp
Values are mean±SEM of 4 experiments performed in duplicate. ⁎pb0.05 vs. basalto basal (cells without treatment). These results were confirmed
by counting cell number in a Trypan blue exclusion test (basal:
(1.10±0.01)104 cells/well; 100 nM carbachol: (1.98±0.02)
104 cells/well; n=4). TMps were less sensitive to the agonist,
since it stimulated by 62% the [3H]-Thymidine uptake with
respect to untreated cells. These results were coincident with cell
counting (basal: (1.30±0.01)104 cells/well; 100 nM carbachol
(2.10±0.02)104 cells/well; n=5).
In addition we tested the action of carbachol in the presence of
different muscarinic antagonists and we observed that NMpsrmal macrophages (NMps). A) Cells were treated with 100 nM carbachol in the
NCDC); 100 μM M NG-monomethyl-L-arginine (L-NMMA), 100 nM H-7 or
estern blot of COX-1 and COX-2 in NMps. Densitometric analysis of the bands
osphate dehydrogenase (GAPDH) protein was used as loading control. One
embrane or cytosol fractions from NMps stimulated with carbachol (100 nM) in
hoctramine (MET) or 1 μM 4-DAMP; one representative experiment of three is
s treated with carbachol in the absence or presence of cyclooxygnase inhibitors.
.
Table 1
cAMP production by macrophages
cAMP (fmol/106 cells/ml) NMps TMps
Basal 172.2±3.4 885.3±34.6
Isoproterenol 966.6±28.1⁎ 2060.3±14.4#
CARB+Isoproterenol 825.4±35.1⁎ 921.7±13.6
AT+CARB+Isoproterenol 1083.9±14.5⁎ 2174.3±19.5#
MET+CARB+Isoproterenol 1143.5±2.9⁎ 1800.4±12.8#
TROP+CARB+Isoproterenol 998.8±7.8⁎ 978.7±11.7
cAMP was determined in macrophages (106 cells/ml) from normal (NMps) or
tumor bearing mice (TMps) incubated during 30 min in the absence or presence
of 1 μM atropine (AT), 1 μM methoctramine (MET) or 1 μM tropicamide
(TROP). Isoproterenol (1 μM) and 100 nM carbachol (CARB) were added for
15 and 25 min respectively. cAMP concentration in samples was expressed in
fentomol per 106 cells and per ml. Values are mean±SEM of 3 experiments
performed in duplicate. ⁎pb0.05 vs. NMps without treatment; #pb0.05 vs.
TMps without treatment.
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receptor blocker and partially reduced by the same concentration
of the M1 selective antagonist pirenzepine. In TMps not only
pirenzepine and methoctramine diminished carbachol stimula-
tory action but also the M3 antagonist 4-DAMP (1 μM) was able
to reduce muscarinic agonist stimulation. The non-selective
muscarinic antagonist, atropine (1 μM) totally blunted carbachol
proliferative actions on both populations of Mps confirming
muscarinic receptors participation. The addition of LPS plus
IFNγ as a positive control, increased the [3H]-Thymidine uptake
in NMps by 65% (basal: 1004.5±98.5 cpm; LPS plus
IFNγ:1655.5±154.5 cpm; pb0,05).
By Western blot and densitometric analysis of the bands, we
confirmed amajor expression ofM1 receptor in both populations
of Mps (Fig. 1C). It is also shown in Fig. 1C that TMps express
lower amounts of M1 and M3 receptor proteins than NMps. On
the contrary, TMps express higher amounts of M2 receptor
subtype in comparison with NMps. In NMps as well as in TMps
M4 receptors are almost undetectable while M5 receptor protein
was absent.
3.2. Protein kinase C and cyclooxygenase are involved in the
proliferative action of carbachol on normal macrophages
Since carbachol-stimulated NMps proliferation was medi-
ated by M1 receptors activation, we investigated whether
phospholipase C-PKC-nitric oxide synthase signaling pathway,
classically coupled to those receptors, was involved in that
effect. It can be seen in Fig. 2A that the stimulatory action of
carbachol on NMps was only reverted by preincubating
cells with 100 nM H-7. The phospholipase C inhibitor, NCDC
or L-NMMA a non-selective nitric oxide synthase inhibitor, did
not reduce carbachol action on NMps. We evidenced that PKC
activation was induced by carbachol because 100% of the active
enzyme was totally located to the cell membrane after treating
NMps during 10 min with 100 nM carbachol (Fig. 2B). This
effect was completely reverted by preincubating cells with
100 nM H-7. We also observed that the addition of 1 μM
methoctramine partially reduced carbachol action on PKC
translocation in NMps (cytosol: 52±4%, membrane: 48±5%).
The addition of 1 μM pirenzepine or 4-DAMP did not modify
carbachol action on PKC translocation.
In general, M2 receptors are linked via the Gi protein to
adenilyl cyclase, reducing cAMP accumulation. We measured
this nucleotide levels in NMps stimulated by 1 μM isoproter-
enol. As shown in Table 1 the addition of 100 nM carbachol
didn't modify the increment in cAMP liberation induced by
isoproterenol (carbachol+ isoproterenol: 825.4±35.1, n=3;
isoproterenol: 966.6±28.1, n=3).
COX-derived prostaglandins are important mediators in
different biological cell activities such as: immune response,
inhibition of cell apoptosis and proliferation. We tested the
participation of COX-derived PGE2 in carbachol-induced pro-
liferation on NMps. In Fig. 2C, is shown that in spite COX-1
expression is higher than COX-2 in NMps, the preincubation of
cells with 1 μM indomethacin or 10 μM NS-398 significantly
reduced carbachol action on NMps proliferation. The addition ofcarbachol significantly increased PGE2 liberation by these cells
in comparison with basal (untreated cells) (Basal: 424.5±48.3
(n=4); carbachol: 746.4±65.8; n=4) (Fig. 2D). When NMps
were previously treated with 1 μMatropine, 1 μMpirenzepine or
1μM4-DAMP, PGE2 liberation was reverted to basal values. On
the contrary, 1 μM methoctramine was unable to modify
carbachol-stimulated PGE2 synthesis (768.3±65.4; n=3). We
also observed that preincubation of cells with 100 nM H-7
potentiates carbachol stimulatory action on PGE2 liberation by
TMps (920.4±89.0) (n=3).
3.3. Arginase and cyclooxygenase are involved in the
proliferative action of carbachol on macrophages derived from
mammary tumor bearing mice
Arginase is the enzyme that converts L-arginine to urea and
ornithine; the latter is needed for polyamine synthesis and cell
proliferation. As shown in Fig. 3A, both isoforms of the enzyme
are expressed in TMps and the proliferative action of 100 nM
carbachol on TMps is significantly reduced by the non-selective
arginase inhibitor NOHA as well as by valine, an amino acid that
interferes arginase pathway, while this effect was not observed in
NMps. We confirmed that arginase is linked to carbachol-
stimulated TMps proliferation since a 3.5 fold increase in urea
formation is observed in comparison with untreated TMps
(Fig. 3B). Muscarinic agonist stimulation on urea formation was
totally reduced not only by 1 μM atropine but also by 1 μM
pirenzepine. Methoctramine partially reduced carbachol-stimu-
lated urea synthesis while 4-DAMP was ineffective.
In addition we observed that COX isoforms are up-regulated
in TMps in comparison with NMps (Fig. 3C) and treatment of
TMps with 1 μM indomethacin or 10 μM NS-398 significantly
reduced carbachol-stimulated [3H]-thymidine incorporation by
TMps. When we measured PGE2 formation in TMps we
observed that 100 nM carbachol dramatically increased its
liberation by 100 fold in comparison with basal (Fig. 3D). Only
the preincubation of cells with 1 μM atropine or 1 μM 4-DAMP
was able to reduce carbachol action on PGE2 liberation,
indicating that M3 receptor subtype is mediating this effect.
Fig. 3. Arginase and cyclooxygenase participation in tumor bearer macrophages (TMps) proliferation. Cells were treated with carbachol (100 nM) in the absence or
presence of A) 100 μM Nω-hydroxy-L-arginine (NOHA) or 50 mM valine. Western blot of arginase (A) I and II in TMps. One representative experiment of three is
shown C) TMps were treated with cyclooxygenase (COX) inhibitors 1 μM indomethacin (INDO) or 10 μMNS-398 previous to carbachol. Western blot of COX-1 and
COX-2 in TMps. Densitometric analysis of the bands was expressed in optical density units per mm2 (O.D./mm2). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) protein was used as loading control. One representative experiment of three is shown B) Arginase activity in TMps stimulated with carbachol (100 nM) in
the absence or presence of: 1 μM atropine (AT), 1 μMpirenzepine (PIR), 1 μMmethoctramine (MET) or 1 μM 4-DAMP. D) Prostaglandin E2 (PGE2) determination in
culture supernatants of TMps treated with carbachol in the absence or presence of COX inhibitors and muscarinic antagonists. Values are mean±SEM of 4 experiments
performed in duplicate. ⁎pb0.05 vs. basal.
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in TMps, we evaluated the function of this receptor subtype by
measuring carbachol action on isoproterenol-stimulated cAMP
levels. It is shown in Table 1 that isoproterenol-stimulated
cAMP synthesis was reduced to basal values by the addition of
100 nM carbachol (Basal: 885.3±34.6; isoproterenol (10−6 M):2060.3±14.4; CARB+isoproterenol: 921.7±13.6; n=3). This
action was reverted by adding 1 μM atropine or 1 μM metho-
ctramine previously to carbachol but not by the same dose of the
M4 receptor antagonist tropicamide.
Preincubation of TMpswith NCDC, L-NMMAor H-7 did not
modify carbachol action on cell proliferation (data not shown).
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Mps perform multiple functions that are essential in tissue
remodelling, wound healing, inflammation and immunity.
Recently, it has been reported the expression of mRNAs
encoding the five mAChR subtypes M1–M5 in immune cells,
including Mps, leading to modulation of their function [15]. We
observe that M1, M2 and M3 receptor proteins are mainly
expressed in Mps derived from normal and LMM3 tumor
bearing mice; but while M1 and M3 receptors are down
regulated in TMps, M2 subtype is up-regulated in this
population of Mps. Stimulation of mAChR with 100 nM
carbachol triggers thymidine uptake and Mps proliferation. This
effect was also observed in different normal cell types as rat
thyroid epithelial cells or scleral chondrocytes generally by
activating diverse metabolic pathways [16,17]. We had
previously reported the presence of mAChR in mouse and
human mammary tumor cells that also stimulate cell prolifera-
tion [18,19]. Our results indicate that while both populations of
Mps equally incorporate [3H}-Thymidine in basal conditions,
NMps are more sensitive to the agonist action at 100 nM than
TMps. The latter could be due to a major expression of M1 and
M3 proteins in NMps than in TMps. The lack of response to
1 μM carbachol exhibited by Mps was also observed by us and
others in different cell types under similar experimental
conditions [20,21]. Desensitization of mAChR and lack of
biological responses, produced by high doses of agonist
(≥1 μM) and/or long incubation periods (≥1 h) has been
largely documented [21,22].
Our results indicate that Mps purified from normal or tumor
bearing mice, majorly express M1 receptors. It has been
extensively documented that these receptors are classically
coupled via Gq/11 protein to phospholipase C-inositol polypho-
sphates hydrolysis that could in turn activate nitric oxide
production by nitric oxide synthase and on the other hand,
diacyl–glycerol–PKC pathway [23]. Surprisingly we observed
that neither phospholipase C inhibitors nor nitric oxide synthase
inhibitors were able to reduce carbachol-stimulated proliferation
in NMps, indicating that PKC could be linked to another
metabolic pathway and/or that could be activated itself by
another mAChR subtype. The latter was confirmed by the
reduction of PKC translocation from cytosol to membrane in
NMps, only by methoctramine, a M2 receptor antagonist. PKCɛ,
an atypical PKC isoform, could be activated by βγ subunit
from Gi protein linked to M2 receptors but not to other receptors
(I.e. M4 or α2c) [24]. This PKC isoform is fully activated by short
time stimulation and lacks of diacyl–glycerol binding site. Other
authors have postulated that in murine Mps, the inhibition of
PKC activity increased PGE2 synthesis by two different mecha-
nisms: regulation of phospholipase A2 activity and induction of
COX-2 protein [25]. Concordantly we observed that PGE2
liberation induced by carbachol in NMps via M1 and M3
receptors activation is enhanced by preincubating cells with H-7
revealing a negative regulatory action of PKC on phospholipase
A2 or COX activity. The fact that H-7 blocked carbachol-
induced proliferation but enhanced PGE2 liberation by 30%
could be indicating two different time-dependent mechanisms,because carbachol stimulation of PGE2 synthesis is a short term
effect, probably due to an increase in PLA2 activity; while H-7
inhibition of proliferation was detected after NMps were
cultured by 48 h, thus it could be acting by inhibiting other
cell signalling steps that must be studied further.
Synthesis of PGE2 via COXwas related to mAChR-G protein
stimulation of phospholipase A2 [26]. Murine peritoneal Mps
expressed both COX proteins as it was stated recently by Luo et
al. [27]. COX-1 and COX-2 protein levels are higher in TMps
than in NMps. Particularly the inhibition of [3H]-Thymidine
uptake due to NS-398 is major than that induced by indo-
methacin only in TMps and the action of carbachol on PGE2
synthesis is dramatically higher than that induced on NMps,
pointing to a major role of COX-2 derived PGE2 on TMps
proliferation.
In addition, Mps are part of the innate immune system and
Mps-derived PGE2 is considered a very important soluble
mediator that acts as a modulator of immune response generally
as an immunosuppressant. PGE2 production in these cells is due
to M3 receptors activation. It has been documented that these
receptors mediate proliferative actions in normal and trans-
formed cells. This effect is also due to an up-regulation of COX-
2 derived PGE2 production [28]. It must be considered that
althoughM3 receptor is expressed at lower level thanM1 andM2
subtypes in TMps, it exerts an important role in cell PGE2
production. Similar results were obtained in our laboratory when
we characterized mAChR expression and function in rat ileal
tissue. M3 receptor is the minor fraction of mAChR expressed in
the ileum, but controls tissue motility via IP3 formation and
calcium mobilization; while M2 subtype, which is mainly
expressed in rat ilieum, inhibits cAMP synthesis facilitating ileal
motility [23].
On the other hand, it has been extensively studied that the
activation of M2 receptors, reduced cAMP accumulation by the
coupling of αi subunit to adenylyl cyclase [22]. The addition of
carbachol to NMps, was not able to reduce isoproterenol-
stimulated cAMP levels confirming uncoupling of this signal-
ling pathway in NMps. By the contrary M2 receptors that are up-
regulated in TMps, are linked to the inhibition in cAMP
concentration produced by carbachol treatment, since it was
reverted by methoctramine. The lack of effect observed with
tropicamide, indicate that although M4 receptors could be
expressed at very low levels in TMps, they are not coupled to the
inhibition of adenylyl cyclase.
Mps are the major component of the mononuclear leukocyte
population of some solid tumors [2,29]. Although the origin of
tumor-infiltrating Mps has been discussed extensively, evi-
dences support both recruitment from the circulating pool of
monocytes and proliferation of the localMps population induced
by stimuli such as growth factors or low oxygen tension as well
as soluble tumor antigens [30]. We had demonstrated that
arginase I and II expression and function are up-regulated in
TMps in comparison with NMps [4]. Here we confirmed that
under muscarinic stimulation arginase metabolites are needed
for TMps proliferation. We had previously reported that TMps
co-inoculated with LMM3 tumor cells promote tumor growth, in
part by stimulating angiogenesis. This effect was also enhanced
89E. de la Torre et al. / Biochimica et Biophysica Acta 1782 (2008) 82–89by carbachol [4,5]. We cannot disregard that urea and ornithine
produced byMps could be used by tumor cells proliferation and/
or endothelial cells sprouting. We also observed that carbachol
dramatically increased PGE2 liberation in TMps via M3 receptor
activation. This effect could be due to a different coupling of the
latter receptor to the effector enzyme. It must be taken into
account that H-7 did not modify carbachol-TMps induced
proliferative action or PGE2 production by these cells.
Our results demonstrate that stimulation of mAChR ex-
pressed in Mps triggers proliferation by using distinct metabolic
pathways depending on their previous activation. On the one
hand, NMps proliferation depends on M2-PKC phosphorylation
signals that turn down the synthesis of PGE2. On the other hand
TMps that are primed by tumor presence, proliferate mainly by
activating arginase pathway via M1 and M2 receptors and by up-
regulating muscarinic-PGE2 synthesis linked to M3 receptor
subtype. These signals could be favouring tumor growth and
host immunosuppression during tumor progression.
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